<a href="https://www.fiercebiotech.com/biotech/makarys-fda-reforms-continue-move-forward-agency-adjusts-leadership-turnover" hreflang="en">Makary’s FDA reforms ‘continue to move forward’ despite leadership turmoil</a>
Despite the resignation of FDA Commissioner Marty Makary, his policy reforms, including the controversial Commissioner’s National Priority Voucher (CNPV) program, will continue under acting commissioner Kyle Diamantas. The FDA is also pushing forward with other initiatives aimed at reducing animal testing and reforming drug approval processes.
The continuation of the FDA's Commissioner’s National Priority Voucher (CNPV) program, despite its controversial expedited review process, presents a significant opportunity for biotechs to achieve faster drug approvals. This could be particularly relevant for those involved in AI-driven drug discovery and digital therapeutics, as aligning with the criteria for CNPV could accelerate time-to-market and potentially outpace competitors.